Kyoto, Japan

Yoshiaki Tomimori

USPTO Granted Patents = 3 


Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2011-2013

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Yoshiaki Tomimori: Innovator in Pharmaceutical Chemistry

Introduction

Yoshiaki Tomimori is a notable inventor based in Kyoto, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds with therapeutic applications. With a total of 3 patents to his name, Tomimori's work is recognized for its potential impact on medical treatments.

Latest Patents

One of Tomimori's latest patents involves a 7-membered ring compound and its method of production, along with its pharmaceutical applications. This 7-membered heterocyclic compound, characterized by the formula (I), exhibits chymase inhibitory action, making it useful for the prevention or treatment of various diseases where chymase is involved. The patent outlines a method for producing this compound, as well as a pharmaceutical composition that includes the compound or its pharmaceutically acceptable salt or solvate.

Career Highlights

Yoshiaki Tomimori is currently employed at Daiichi Sankyo Company, Limited, where he continues to advance his research in pharmaceutical innovations. His work has contributed to the development of new therapeutic agents that hold promise for treating a range of health conditions.

Collaborations

Tomimori has collaborated with esteemed colleagues such as Tsuyoshi Muto and Taisaku Tanaka. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.

Conclusion

Yoshiaki Tomimori's contributions to pharmaceutical chemistry through his innovative patents highlight his role as a key inventor in the field. His work not only advances scientific knowledge but also has the potential to improve patient outcomes through new therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…